Renal Cell Carcinoma

• Autor principal: López, José I. (auth)
• Formato: Recurso Electrónico Capítulo de Livro
• Idioma: inglês
• Publicado em: MDPI - Multidisciplinary Digital Publishing Institute 2020
• Assuntos: Biology, life sciences; N-glycomapping; n/a; SMAD proteins; patient survival; pro-IL-1?; survival prediction; inflammation markers; tumor migration; prognostic factors; practical approach; circular RNAs in a clinico-genomic predictive model; glycomarkers; review; nephrectomy; uric acid; VEGF inhibitors; metabolic reprogramming; collecting duct carcinoma; curcumin; metabolome profiling; identification of circular RNAs; IL-2; experimental validation of circular RNA; Raf/MEK/ERK; HOT; PI3K/Akt/mTOR; pentose phosphate pathway; kidney cancer; LOT; mutation; RCC; polybromo-1; pale cell; MMP-9; gene expression; recurrence free survival; chromosomal loss; IL-1?; chronic kidney disease; glutathione transferase omega 2; label-free; glutathione transferase omega 1; emerging entity; copy number alteration; FOXO3; predictive role; tumor slice culture; tyrosine kinase inhibitors; PPP; ESC; CDKN1A expression; metastasis; PD-L1; diagnostic and prognostic markers; EVI1; copy number loss; RNA sequencing; NK cells; glutathione metabolism; clear cell renal cell carcinoma; renal cell cancer; proliferation; eosinophilic variant; Xp11 translocation renal cell carcinoma; prognosis; invasion; immune infiltration; IL4R?; FISH; 11) translocation renal cell carcinoma; tumor microenvironment; metabolome; hyperosmolality; toxicity; ALK; drug sensitivity; t(6; copy number analysis; urine; genetic association; polymorphism; solute carrier proteins; kidney; metastatic ccRCC; molecular genetic features; recurrence-free survival; chromophobe renal cell carcinoma; unclassified renal tumor; overall survival; mTOR inhibitors; mTOR; JAK2; von Hippel-Lindau; miR-155-5p; glycoproteomics; PBRM1; miR-133b; survival; TFE3; TFEB; oncocytic renal tumor; immune checkpoint inhibitors; biomarker; MMP10; TCGA; ghrelin; EMT like; checkpoint inhibitors; MiT family translocation renal cell carcinoma; gene signature; sarcomatoid; transforming growth factor beta; clear cell Renal Cell Carcinoma; tumor adhesion; renal cancer; unclassified renal cell carcinoma; Papillary renal cell carcinoma (pRCC); miR-146a-5p; renal cell; everolimus; integrins; cytoreductive nephrectomy; immunotherapy; predictive factors; immunohistochemistry; MTA2; IL13R?1; targeted therapy; intratumour heterogeneity; aurora A; TCA cycle; AMP-activated protein kinases; cancer-specific survival; programmed death-ligand 1; efficacy; renal cell carcinoma; anaplastic lymphoma kinase rearrangement; TFEB-amplified renal cell carcinoma; statins; cancer immunotherapy; microRNA; new entity; proteome profiling
• Acesso em linha: DOAB: download the publication; DOAB: description of the publication

Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. T...